Eoghan O’Leary
Vice President of Research Circio AB
Eoghan O’Leary is Vice President of Research at Circio Holding ASA, where he leads research activities across the company’s RNA technology platform. He has progressed through several research leadership roles at Circio, previously serving as Director of RNA Research and Research Scientist.
Before joining Circio, Eoghan completed his PhD at Aarhus University, building a strong academic foundation in molecular and RNA-focused research. His experience spans early-stage research, RNA platform development and the translation of emerging RNA technologies towards therapeutic applications.
Seminars
Friday 19th February 2027
Harnessing circRNA Stability to Increase Expression, Reduce Dose & Expand into In Vivo CAR-T
3:30 pm
- Potent, durable expression – circVec harnesses the intrinsic stability of circular RNA to accumulate transcripts intracellularly, delivering more protein per vector and sustaining expression far longer than conventional mRNA-based systems
- Dose-sparing AAV gene therapy – by amplifying expression per vector genome, circVec enables robust therapeutic output at substantially lower AAV doses, with dose reduction demonstrated in both heart and eye – offering the potential to widen the therapeutic window and reduce dose-related toxicity
- Expanding in vivo CAR-T using targeted LNPs and cell-specific expression to improve immune-cell targeting
